Trial Profile
A phase IIIB, randomized trial of open-label efavirenz or atazanavir with ritonavir in combination with double-blind comparison of emtricitabine/tenofovir or abacavir/lamivudine in antiretroviral-naive subjects.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Jul 2023
Price :
$35
*
At a glance
- Drugs Atazanavir (Primary) ; Efavirenz (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Lamivudine/abacavir (Primary) ; Ritonavir (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- 19 Apr 2021 Results assessing the Association Between Weight Gain, Sex and Immune Activation Following the Initiation of Antiretroviral Therapy from two trials A5202 and A5257 published in the Journal of Infectious Diseases
- 23 Aug 2020 Results (n=757) of a retrospective, observational cohort of individuals receiving primary care at the vanderbilt comprehensive care clinic and a retrospective analysis of a clinical trials (A5095, A5142 and A5202 and did not receive INSTIs) cohort from efavirenz containing arms of ACTG protocols has been published in the Clinical Infectious Diseases.
- 07 Mar 2018 Results presented at the 25th Conference on Retroviruses and Opportunistic Infections